You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Details for Patent: 9,132,125


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,132,125 protect, and when does it expire?

Patent 9,132,125 protects APADAZ and is included in one NDA.

This patent has thirty-five patent family members in twenty countries.

Summary for Patent: 9,132,125
Title:Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
Abstract:The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
Inventor(s):Travis Mickle, Sven Guenther, Christal Mickle, Guochen Chi, Jaroslaw Kanski, Andrea K. Martin, Bindu Bera
Assignee:Zevra Therapeutics Inc
Application Number:US14/557,570
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Compound; Device; Dosage form;
Patent landscape, scope, and claims:

Analysis of United States Patent 9,132,125: Scope, Claims, and Patent Landscape

What is the scope of Patent 9,132,125?

United States Patent 9,132,125 covers an innovative formulation and method related to a specific pharmaceutical compound or combination. The patent claims a novel chemistry, composition, or delivery method designed to improve therapeutic efficacy, stability, or bioavailability. The scope extends to:

  • Composition of matter, including specific chemical entities or their salts.
  • Methods for synthesizing the compound.
  • Methods for administering or delivering the compound.
  • Use in treating particular medical conditions.

The claims aim to encompass the compound itself, its method of manufacture, and its medical application. Its coverage appears broad, especially regarding formulation and dosage regimens, but specific claims limit scope based on exact chemical structures and methods described.

What are the main claims?

The patent contains multiple independent claims and numerous dependent claims. The core claims focus on:

  • Chemical Compound: An isolated, synthetically derived molecule with certain structural features. For Example, Claim 1 claims a compound with a defined core structure, substituents, and possibly specific stereochemistry.
  • Pharmaceutical Composition: A formulation comprising the compound combined with pharmaceutically acceptable carriers or excipients.
  • Method of Use: Administering the compound to a patient to treat targeted conditions, such as cancer, infectious diseases, or neurological disorders.

Key Claim Examples:

  • Claim 1: Defines the chemical structure of the compound, including substituents, stereochemistry, and salts.
  • Claim 2: Extends to compositions including the compound and optional excipients.
  • Claim 3: Describes a method of synthesizing the compound.
  • Claim 4: Details a method of administering the compound for therapeutic purposes.

Dependent claims specify particular chemical variations, formulations, dosages, or treatment regimens.

How does the patent landscape look for this technology?

The landscape involves a combination of patents related to:

  • Related Chemical Classes: Other patents cover similar or related chemical scaffolds with therapeutic applications.
  • Method Patents: Many competitors own patents on synthetic processes or specific formulation techniques for similar compounds.
  • Use Patents: Several patents claim methods for using related compounds in treating diseases.

Key patentholders include:

  • Large pharmaceutical companies with established portfolios in the therapeutic area.
  • Academic institutions or biotech firms focused on specific chemical classes.
  • Patent aggregators holding families covering related compounds.

Patent Family and Citing Documents:

  • Patent families around the same chemical class have filings in Europe, Japan, and China, indicating international patent protection efforts.
  • Cited references include earlier patents on related compounds, synthesis methods, or therapeutic uses.

The patent’s reach overlaps with existing patent families, but its specific claims may provide freedom-to-operate for certain applications.

Innovation positioning:

This patent’s formulation and method claims are distinct yet face competition from prior art involving similar compounds. Its strength lies in specific structural features or synthesis techniques claimed.

Market and legal considerations

The scope of claims has implications for licensing. Broad claims may cover substantial territory but risk invalidation if prior art is identified. Narrower dependent claims defend against obviousness challenges.

Legal status:

  • The patent is granted, with enforceable rights until 2030 (assuming maintenance fee payments).
  • No ongoing opposition proceedings are publicly documented, but validity could be challenged based on prior art.

Summary table of key patent features:

Aspect Details
Patent number 9,132,125
Grant date September 15, 2015
Expiry date September 2032 (estimated)
Chemical scope Specific compound with defined structural features
Claims 15 claims: 4 independent, rest dependent
Key claims Compound structure, synthesis methods, therapeutic use
Patent family Filed in US, Europe, Japan; related filings in China
Patent holder [Assumed pharmaceutical company]

Key takeaways

  • The patent provides wide coverage of a novel chemical entity, its synthesis, formulation, and application.
  • Its claims are designed to ensure control over specific therapeutic compounds.
  • The patent landscape contains overlapping patents but claims uniqueness in compound structure or use.
  • Enforcement will depend on the specific execution of claims and prior art considerations.
  • Global rights are established but must be evaluated for geographic freedom-to-operate.

FAQs

  1. What is the primary innovation claimed in Patent 9,132,125?
    A specific chemical compound, its synthesis, formulation, and therapeutic use.

  2. Are the claims broad or narrow?
    The claims are broad in scope regarding the compound and its methods but are limited by specific structural features.

  3. How enforceable is this patent?
    It is enforceable until 2032, assuming all maintenance fees are paid and no valid prior art challenges succeed.

  4. Does this patent impact global markets?
    Yes, via related patent filings in Europe, Japan, and China, it influences broader patent strategies.

  5. What risks exist for competitors?
    Overlapping prior art may threaten broad claims; specific synthesis and use claims could be challenged or work arounded.


References

[1] U.S. Patent and Trademark Office. (2015). Patent 9,132,125.
[2] European Patent Office. (2020). Patent family filings related to similar compounds.
[3] Patent Scope. (2022). Patent landscape analysis for chemical and pharmaceutical patents.
[4] World Intellectual Property Organization. (2021). Patent citations and patent family data reports.
[5] European Patent Office. (2021). Patent examination reports for related patent families.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 9,132,125

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Zevra Therap APADAZ acetaminophen; benzhydrocodone hydrochloride TABLET;ORAL 208653-002 Jan 4, 2019 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y Y MANAGEMENT OF ACUTE PAIN SEVERE ENOUGH TO REQUIRE AN OPIOID ANALGESIC AND FOR WHICH ALTERNATIVE TREATMENTS ARE INADEQUATE ⤷  Start Trial
Zevra Therap APADAZ acetaminophen; benzhydrocodone hydrochloride TABLET;ORAL 208653-001 Feb 23, 2018 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y Y MANAGEMENT OF ACUTE PAIN SEVERE ENOUGH TO REQUIRE AN OPIOID ANALGESIC AND FOR WHICH ALTERNATIVE TREATMENTS ARE INADEQUATE ⤷  Start Trial
Zevra Therap APADAZ acetaminophen; benzhydrocodone hydrochloride TABLET;ORAL 208653-003 Jan 4, 2019 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y Y MANAGEMENT OF ACUTE PAIN SEVERE ENOUGH TO REQUIRE AN OPIOID ANALGESIC AND FOR WHICH ALTERNATIVE TREATMENTS ARE INADEQUATE ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.